Nevro
Founded 2006 · 903 employees on LinkedIn · 2 known investors
Nevro develops spinal cord stimulation (SCS) systems for the treatment of chronic pain, including FDA-approved indications for painful diabetic neuropathy and non-surgical back pain. Its offerings are aimed at physicians and patients seeking long-term chronic pain relief.
Investors · 2
Frequently asked questions
- What does Nevro do?
- Nevro develops spinal cord stimulation (SCS) systems for the treatment of chronic pain, including FDA-approved indications for painful diabetic neuropathy and non-surgical back pain. Its offerings are aimed at physicians and patients seeking long-term chronic pain relief.
- Who are Nevro's investors?
- Nevro's investors include Bay City Capital, New Enterprise Associates (NEA).